The abstract is read at the publisher; the summary is JClub's.
A 2026 Pediatric Oncology Group of Ontario guideline update maintains conditional antibacterial prophylaxis consideration in pediatric AML and relapsed ALL and strongly recommends levofloxacin when planned.
- Why it matters: Clinicians need harmonized, evidence-graded guidance for preventing bacterial and fungal infections in children with cancer and hematopoietic cell transplant recipients, where prophylaxis choices vary.
- What they did: The panel updated systematic reviews of randomized trials and used GRADE to revise recommendations, incorporating 13 new trials since 2019 for 195 total trials.
- The result: It maintains strong antifungal prophylaxis recommendations for pediatric AML and allogeneic HCT and supports echinocandin or mold-active azole use when planned, adding good practice statements on interactions, prevention, and epidemiology monitoring.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.